JO3462B1 - أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها - Google Patents

أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Info

Publication number
JO3462B1
JO3462B1 JOP/2013/0245A JOP20130245A JO3462B1 JO 3462 B1 JO3462 B1 JO 3462B1 JO P20130245 A JOP20130245 A JO P20130245A JO 3462 B1 JO3462 B1 JO 3462B1
Authority
JO
Jordan
Prior art keywords
span
antibodies
methods
gfrα3
dir
Prior art date
Application number
JOP/2013/0245A
Other languages
English (en)
Inventor
Susan D Croll
Lynn Macdonald
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49036666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3462(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3462B1 publication Critical patent/JO3462B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم أجسام مضادة ترتبط مع <span dir="LTR">GFRα3</span> البشري وطرق لاستخدامها. وفقا لنماذج معينة للاختراع، تكون الأجسام المضادة عبارة عن أجسام مضادة بشرية بصورة كاملة ترتبط مع <span dir="LTR">GFRα3</span> البشري. الأجسام المضادة الخاصة بالاختراع مفيدة في علاج أمراض واضطرابات تصاحب واحدا أو أكثر من الأنشطة الحيوية لـ <span dir="LTR">GFRα3</span>، بما في ذلك علاج حالات الألم الحاد أو المزمن، أو الحالات الالتهابية.
JOP/2013/0245A 2012-08-22 2013-08-15 أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها JO3462B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261692029P 2012-08-22 2012-08-22

Publications (1)

Publication Number Publication Date
JO3462B1 true JO3462B1 (ar) 2020-07-05

Family

ID=49036666

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0245A JO3462B1 (ar) 2012-08-22 2013-08-15 أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Country Status (34)

Country Link
US (5) US8968736B2 (ar)
EP (2) EP3450458B1 (ar)
JP (3) JP6392755B2 (ar)
KR (1) KR102158569B1 (ar)
CN (2) CN109096398A (ar)
AR (1) AR092188A1 (ar)
AU (1) AU2013305863B2 (ar)
CA (1) CA2879724C (ar)
CL (1) CL2015000420A1 (ar)
CY (1) CY1121097T1 (ar)
DK (1) DK2888280T3 (ar)
EA (2) EA202090031A3 (ar)
ES (1) ES2700160T3 (ar)
HR (1) HRP20190109T1 (ar)
HU (1) HUE042943T2 (ar)
IL (1) IL236738B (ar)
JO (1) JO3462B1 (ar)
LT (1) LT2888280T (ar)
MA (1) MA37945B1 (ar)
MX (1) MX363541B (ar)
MY (2) MY167920A (ar)
NZ (1) NZ704007A (ar)
PH (1) PH12015500114B1 (ar)
PL (1) PL2888280T3 (ar)
PT (1) PT2888280T (ar)
RS (1) RS58311B1 (ar)
SG (2) SG10201701376UA (ar)
SI (1) SI2888280T1 (ar)
SM (1) SMT201900022T1 (ar)
TR (1) TR201816597T4 (ar)
TW (2) TWI613218B (ar)
UY (1) UY34988A (ar)
WO (1) WO2014031712A1 (ar)
ZA (1) ZA201500336B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
WO2016025884A1 (en) * 2014-08-14 2016-02-18 The Trustees Of The University Of Pennsylvania Glycosyl-phosphatidylinositol (gpi)-linked gdnf family alpha-receptor 4 (gfralpha4)-specific antibody and uses thereof
RU2732502C2 (ru) 2016-02-10 2020-09-18 Ратгерс, Де Стейт Юниверсити Оф Нью Джерси Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis
US20170281756A1 (en) * 2016-02-25 2017-10-05 University Of Southern California Compositions and methods to selectively block pain induced by cold
WO2017147742A1 (en) * 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
CN117986363A (zh) * 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
MX2018013885A (es) 2016-05-13 2019-08-16 Inst De Medicina Molecular Joaeo Lobo Antunes Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
CN107827983B (zh) * 2017-11-06 2020-09-25 中国药科大学 一种靶向artn的单链抗体、制备方法及应用
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途
WO2019210144A1 (en) * 2018-04-27 2019-10-31 Vanderbilt University Broadly neutralizing antibodies against hepatitis c virus
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
KR20210134321A (ko) * 2019-02-01 2021-11-09 노바록 바이오테라퓨틱스 리미티드 항-클라우딘 18 항체 및 이의 이용 방법
CA3134258A1 (en) * 2019-04-10 2020-10-15 Regeneron Pharmaceuticals, Inc. Human antibodies that bind ret and methods of use thereof
US11802159B2 (en) 2019-09-30 2023-10-31 The Trustees Of The University Of Pennsylvania Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2023012300A (es) 2021-04-20 2023-10-26 Regeneron Pharma Anticuerpos humanos contra artemina y metodos de uso de estos.
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位
US20250154236A1 (en) * 2022-01-31 2025-05-15 Glaxosmithkline Intellectual Property (No. 3) Limited Prevention and treatment of headaches
WO2024155798A1 (en) * 2023-01-18 2024-07-25 Texas Tech University System Gfra2 antibodies and their use in cancer treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
DE69930374T2 (de) 1998-03-23 2006-12-07 Genentech, Inc., South San Francisco Gfr-alpha3 und seine verwendungen
BR9912819A (pt) * 1998-07-14 2001-05-02 Janssen Pharmaceutica Nv Fator de crescimento neurotrófico
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20090202562A1 (en) * 2005-06-17 2009-08-13 Biogen Idec Ma Inc. Anti-gfralpha3 antibodies
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
KR20100021601A (ko) * 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
WO2009013543A2 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to kdr and uses thereof - 035
EP2205634A2 (en) 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
KR20130132904A (ko) * 2010-12-06 2013-12-05 다이닛본 스미토모 세이야꾸 가부시끼가이샤 인간 모노클로날 항체
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Also Published As

Publication number Publication date
MY184241A (en) 2021-03-29
US8968736B2 (en) 2015-03-03
WO2014031712A1 (en) 2014-02-27
HK1206037A1 (en) 2015-12-31
CA2879724A1 (en) 2014-02-27
RS58311B1 (sr) 2019-03-29
SI2888280T1 (sl) 2019-03-29
KR102158569B1 (ko) 2020-09-22
CA2879724C (en) 2023-03-14
CY1121097T1 (el) 2019-12-11
EA201590402A1 (ru) 2015-09-30
US20170096488A1 (en) 2017-04-06
UY34988A (es) 2014-03-31
PH12015500114A1 (en) 2015-03-16
DK2888280T3 (en) 2018-12-10
CN109096398A (zh) 2018-12-28
PL2888280T3 (pl) 2019-04-30
JP6392755B2 (ja) 2018-09-19
CL2015000420A1 (es) 2015-05-22
SMT201900022T1 (it) 2019-02-28
PH12015500114B1 (en) 2015-03-16
US20200040087A1 (en) 2020-02-06
MA37945B1 (fr) 2017-05-31
NZ704007A (en) 2018-08-31
TW201420603A (zh) 2014-06-01
US20150110801A1 (en) 2015-04-23
EP2888280B1 (en) 2018-10-17
JP2018143252A (ja) 2018-09-20
SG11201500501VA (en) 2015-02-27
AU2013305863B2 (en) 2018-06-07
EP2888280A1 (en) 2015-07-01
EP3450458A1 (en) 2019-03-06
US10077311B2 (en) 2018-09-18
LT2888280T (lt) 2018-12-10
MA37945A1 (fr) 2016-02-29
TR201816597T4 (tr) 2018-11-21
EA202090031A3 (ru) 2020-07-31
US10947312B2 (en) 2021-03-16
JP6718482B2 (ja) 2020-07-08
MY167920A (en) 2018-09-27
US20180340029A1 (en) 2018-11-29
AR092188A1 (es) 2015-04-08
MX363541B (es) 2019-03-27
HUE042943T2 (hu) 2019-07-29
EP3450458B1 (en) 2021-07-14
TWI631139B (zh) 2018-08-01
IL236738B (en) 2022-04-01
AU2013305863A1 (en) 2015-02-05
CN104768974A (zh) 2015-07-08
ES2700160T3 (es) 2019-02-14
TWI613218B (zh) 2018-02-01
JP2020031662A (ja) 2020-03-05
HRP20190109T1 (hr) 2019-03-08
JP2015532647A (ja) 2015-11-12
CN104768974B (zh) 2018-08-14
ZA201500336B (en) 2019-12-18
SG10201701376UA (en) 2017-03-30
US9522185B2 (en) 2016-12-20
TW201819415A (zh) 2018-06-01
KR20150041664A (ko) 2015-04-16
PT2888280T (pt) 2019-01-21
EA034683B1 (ru) 2020-03-05
EA202090031A2 (ru) 2020-04-30
US20140056903A1 (en) 2014-02-27
MX2015002289A (es) 2016-06-07
IL236738A0 (en) 2015-02-26
BR112015003110A2 (pt) 2018-08-28

Similar Documents

Publication Publication Date Title
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MY165273A (en) Anti-cd48 antibodies and uses thereof
MX2015010749A (es) Anticuerpos humanos para nav1.7.
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
UA104663C2 (xx) Антитіло, що зв&#39;язує cd127$антитело, связывающее cd127
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
MX2015017853A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
CA2862332C (en) Anti-asic1 antibodies and uses thereof
PH12015502829A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
MX366046B (es) Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201990403A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
EA201401142A1 (ru) Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3
BR112015014768A2 (pt) anticorpos anti-gdf15